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Abstract In this study we characterized the subtypes of
nucleotide P2Y receptors that respond to ADP in glioma C6
cells. Direct visualization of phosphatidylinositol 4,5-bisphos-
phate at the cell surface revealed that extracellular ADP
activates phospholipase C (PLC). Knock-down of P2Y1 receptor
with antisense oligonucleotide, as well as treatment with
MRS2179 and pyridoxal-phosphate-6-azophenyl-2P,4P-disulfonic
acid (P2Y1 antagonists), attenuates receptor-mediated PLC
activity. Adenylyl cyclase inhibition by ADP remains unchanged
under these conditions. Reverse transcription-PCR analysis
showed that P2Y12 receptor is expressed in C6 cells. We
therefore conclude that, in glioma C6 cells, two P2Y receptor
subtypes are present: P2Y1, coupled to PLC, and P2Y12,
negatively coupled to adenylyl cyclase. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Extracellular adenine and uridine nucleotides act through
two families of membrane bound P2 receptors: P2Y subtypes,
all of which are G protein-coupled receptors, generally
coupled to phospholipase C (PLC), and P2X subtypes which
are ligand-gated channels [1]. Within the family of P2Y recep-
tors, P2Y1 responds selectively to ADP and is partially antag-
onized by ATP, while the P2Y2 receptor responds both to
ATP and UTP [2]. P2Y1 receptor was ¢rst cloned from chick
[3], and then successively from turkey [4], rat and mouse [5],
bovine [6] and human tissues [7]. All of them activate PLC.
While extracellular ADP has been reported to stimulate
PLC activity in various cells, with the resulting production
of inositol 1,4,5-trisphosphate (InsP3) and diacylglycerol [8],
there are examples where ADP activates P2Y receptor
coupled to the inhibition of adenylyl cyclase [9^11]. Studies
on glioma C6-2B and C6 cells have shown the presence of a
P2Y1-like receptor. This receptor inhibits adenylate cyclase
with similar agonists but dissimilar antagonists as P2Y1 re-
ceptor. Also, it is believed not to be coupled to PLC [9,11^14].
We have recently found that glioma C6 cells express two
types of nucleotide receptors, of molecular and pharmacolog-
ical identity consistent with P2Y1 and P2Y2, which both lead
to PLC activation [15]. We have provided several lines of
evidence that ADP acts on the P2Y1 receptor coupled to
PLC and elevated cytosolic Ca2. It has been demonstrated
that, in glioma C6 cells, ADP has two activities : it stimulates
PLC and mobilizes [Ca2], and inhibits adenylyl cyclase. This
e¡ect was pertussis toxin (PTX)-sensitive, suggesting Gi pro-
tein involvement. In conclusion, we supposed that either the
single P2Y1 receptor was involved in both activities, or that
two receptors were present in these cells : the cloned P2Y1
receptor and yet-to-be cloned P2Y1-like receptor coupled to
adenylyl cyclase [15]. Most recently, a P2Y receptor subtype
that couples to the inhibition of adenylyl cyclase in rat blood
platelets, previously termed P2TAC, has been cloned and des-
ignated P2Y12 [16]. The presence of this receptor has also been
reported in C6-2B glioma cells [17]. Therefore, the aim of this
study was to di¡erentiate whether ADP acts on one (coupled
to di¡erent G proteins) or two distinct P2Y receptors in glio-
ma C6 cells and to characterize the functional P2Y1-like re-
ceptor associated with adenylyl cyclase.
In the present study we ¢rst con¢rm our previous results
showing that ADP stimulates PLC by using the direct visual-
ization of phosphatidylinositol 4,5-bisphosphate (PIP2) at the
cell surface. Second, using an antisense oligonucleotide tech-
nique, we demonstrate that knock-down of the P2Y1 receptor
causes a decrease in the P2Y1 mRNA level and loss of the
receptor-evoked PLC activity, whereas the ADP-generated in-
hibition of adenylyl cyclase remains unchanged. Third, we
reveal, using reverse transcription-PCR (RT-PCR) analysis,
that the P2Y12 receptor is expressed in glioma C6 cells. There-
fore, we conclude that, in these cells, two ADP-responding
receptors coexist : P2Y1 linked to PLC, and P2Y12 negatively
coupled to adenylyl cyclase through Gi.
2. Materials and methods
2.1. Materials
Minimum essential medium (MEM), calf serum, antibiotics, Lipo-
fectamine 2000, Trizol reagent and phosphate-bu¡ered saline (PBS)
were from Gibco BRL. TRI reagent, ADP, bovine serum albumin
0014-5793 / 02 / $22.00 ß 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 2 5 5 - X
*Corresponding author. Fax: (48)-22-8225342.
E-mail address: baranska@nencki.gov.pl (J. Baran¤ska).
1 Permanent address: Department of Pharmacology, The First
Military University, Guangzhou, PR China.
Abbreviations: [Ca2]i, intracellular Ca2 concentration; GFP, green
£uorescent protein; InsP3, inositol 1,4,5-trisphosphate; MEM, mini-
mum essential medium; PIP2, phosphatidylinositol 4,5-bisphosphate;
PLC, phospholipase C; PPADS, pyridoxal-phosphate-6-azophenyl-
2P,4P-disulfonic acid; PTX, pertussis toxin
FEBS 25744 11-3-02 Cyaan Magenta Geel Zwart
FEBS 25744 FEBS Letters 513 (2002) 179^183
(BSA), EGTA, ethidium bromide, agarose, molecular weight marker
(123 bp) were purchased from Sigma Chemical Co. Fura-2/AM was
from Molecular Probes, Inc. Pyridoxal-phosphate-6-azophenyl-2P,4P-
disulfonic acid (PPADS) was obtained from Research Biochemicals
International. Expand RT enzyme was purchased from Roche. Taq
PCR core kit, Qiaex and EndoFree kits were obtained from Qiagen.
TransFast reagent was obtained from Promega. MRS2179 tetraam-
monium salt was from Tocris. Cyclic AMP (cAMP) assay kit was
from Amersham Pharmacia Biotech.
2.2. Cell culture
Glioma C6 cells (passages 40^60) were cultured in MEM supple-
mented with 10% (v/v) calf serum, penicillin (50 IU/ml), streptomycin
(50 Wg/ml) and 2 mM L-glutamine under a humidi¢ed atmosphere of
5% CO2 at 37‡C.
2.3. Measurement of intracellular calcium
Intracellular Ca2 levels were measured as described previously [18]
with the following modi¢cations. Cells on coverslips were washed
once with PBS and once with the solution containing: 137 mM
NaCl, 2.7 mM KCl, 1 mM Na2HPO3, 25 mM glucose, 20 mM
HEPES (pH 7.4), 1 mM MgCl2, 1% (v/v) BSA and 2 mM CaCl2
(standard bu¡er). The cells were incubated at 37‡C for 30 min in
the standard bu¡er with 1 WM Fura-2/AM. Thereafter, the cells
were washed with the standard bu¡er and coverslips were mounted
in a chamber over a Nikon Diaphot inverted-stage microscope
equipped with a U40 oil-immersion £uorescence objective lens. Dig-
ital £uorescence microscopy was used to determine the changes in
[Ca2]i. Experiments were carried out on a video imaging system
(MagiCal, Applied Imaging Ltd.). The cells were alternatively illumi-
nated with 340 and 380 nm wavelengths of light from a xenon lamp.
The emitted light was passed through a 510 nm barrier ¢lter into an
image-intensi¢ed camera (Extended ISIS, Photonic Science). The 340
nm and 380 nm images (256 gray levels) were software averaged and
captured every 2.85 s. The 340 nm and 380 nm signals were examined
for real changes in [Ca2]i. Ratio (R) values were converted to an
estimate of [Ca2]i according to Grynkiewicz et al. [19]. Data process-
ing and ratio value conversion to [Ca2]i were carried out using Tar-
dis V8.0 software.
2.4. Measurement of intracellular cAMP
The adenylyl cyclase activity was estimated by measuring isoproter-
enol (50 WM)-stimulated cAMP accumulation according to Lin and
Chuang [20], assayed with the [3H]cAMP assay kit. Cell pellets were
assayed for protein content by a modi¢cation [21] of the procedure of
Lowry et al. [22], and the level of cAMP was expressed in pmol per
mg of protein.
2.5. Isolation of P2Y1 and P2Y12 mRNA and RT-PCR analysis
Total RNA was extracted from glioma C6 cells using TRI reagent.
Reverse transcription of total RNA (1 Wg) was performed using Ex-
pand RT enzyme. Speci¢c primers for the PCR reaction were designed
using ‘DNA Star’ software (DNA Star Inc. USA). P2Y1 primers were
based on unique sequences stretching bases 97^120 (5P-AGA ATG
CGG CCG GAA GAA GAG TCG-3P, upper) and 686^666 (5P-
AGC CCA GGC CAG CCA GGA AGG-3P, lower) of the rat
P2Y1 sequence (accession no. U22830). The estimated product length
was 590 bp. P2Y12 primers were based on the following unique se-
quences: 533^554 (5P-AAA CTT CCA GCC CCA GCA ATC T-3P,
upper) and 1021^1002 (5P-CAA GGC AGG CGT TCA AGG AC-3P,
lower) of the rat P2Y12 sequence (accession no. L46865). The pre-
dicted product length was 489 bp. A hot-start PCR protocol was
used involving denaturation at 95‡C, annealing at 65‡C (P2Y1) or
56‡C (P2Y12) and extension at 72‡C. A total of 30 cycles were con-
ducted. PCR products were separated on 1% agarose gels, stained
with ethidium bromide and quanti¢ed using ImageQuant and Excel
programs.
2.6. Construction of fusion protein
Total RNA was prepared from mouse brain using Trizol reagent.
Reverse transcription of total RNA was performed using Expand RT
enzyme. The pleckstrin homology (PH) domain of PLCN1 (1^170) was
ampli¢ed with Taq PCR core kit (Qiagen) and the following primer
pair:
Upper: 5P-ATATAGATCTAGGCCGCTTGGTGATTTT-3P
Lower: 5P-ATATGTCGACCCTCCCGCTGCTGATGC-3P
A hot-start PCR protocol was used involving denaturation at 95‡C,
annealing at 60‡C and extension at 68‡C. A total of 35 cycles were
conducted. PCR products were separated on 1% agarose gels, and
isolated using Qiaex gel extraction kit. The PCR product was sub-
cloned in-frame into the BglII site of green £uorescent protein (GFP)
mammalian expression vector pS65T-C1 (Clontech). The ¢nal product
encoding the PH domain of mouse PLCN1 fused to the C-terminus of
GFP was used for transfection.
2.7. Glioma C6 cells transfection and microscopy methods
Cells were plated on coverslips and cultured in 35 mm diameter
dishes for 2 days, reaching approximately 80% con£uency. Plasmid
DNA for transfection was prepared using an EndoFree plasmid iso-
lation kit. 1 Wg of plasmid DNA was used for each transfection.
Transfection was performed using TransFast reagent according to
the manufacturer’s instructions. A 3:1 TransFast:DNA ratio was
used, giving reasonable e⁄ciency (approximately 20%) and low cyto-
toxicity. Two days after transfection, cells were washed with standard
bu¡er and viewed under a Zeiss Axiovert microscope using a digital
video imaging system equipped with a CCD Micromax 1300 YHS
camera (Princeton Instruments) and MetaMorph software. A 480
nM £uorescence ¢lter and U100 oil-immersion objective were used.
Z-scans of the cells were taken before and 5 min after agonist addi-
tion. Simultaneously, calcium measurement was performed with
MetaFluor software in the subjected cells using Fura-2 imaging as
described above, without conversion of the ratio values to [Ca2]i.
Z-scans were processed with AutoDeblur software using a blind de-
convolution method.
2.8. Antisense oligonucleotide sequence and delivery
The antisense oligonucleotide sequence (5P-ACC TCG GTC ATC
CTC-3P) was designed on the basis of the published sequence of P2Y1
receptor (accession no. U22830). It covered 15 bp around the ATG
start site of translation. The sense oligonucleotide was used as a con-
trol. Phosphothioate oligonucleotides were commercially synthesized
and puri¢ed by high-performance liquid chromatography. For knock-
down experiments, cells were grown on 35 mm diameter petri dishes
(for cAMP assay) or on coverslips in 35 mm petri dishes (for intra-
cellular calcium measurement) for 2 days reaching approximately 90%
con£uency. The oligonucleotides (5 Wg per dish) were delivered in
MEM without serum and antibiotics using Lipofectamine 2000 re-
agent according to the manufacturer’s instructions. After 4 h, the
medium was replaced by serum containing MEM and the cells were
allowed to recover for 20 h. Then, the procedure was repeated. The
cells were analyzed 24 h after the second transfection. The e⁄ciency of
this method of transfection reached 50%, as estimated with pS65T-C
plasmid expressing GFP.
3. Results
The discovery that the PH domain of PLCN binds PIP2 with
high a⁄nity and selectivity makes this domain a powerful
probe for determining the subcellular localization of this
phospholipid [23]. In this study, we tested the binding specif-
icity of the PH domain of PLCN, expressed as a GFP fusion
protein (PH(PLCN) GFP) in glioma C6 cells. Digital £uores-
cence microscopy of PH(PLCN) GFP-transfected glioma C6
cells revealed that the expressed protein was found within the
cell. As shown in Fig. 1A, a distinct amount of fusion protein
was constitutively present at the plasma membrane, indicating
that, in unstimulated cells, PIP2 resides in this compartment.
Stimulation with ADP caused a rise in the intracellular cal-
cium level (Fig. 1B). Simultaneously with the increase in
[Ca2]i, a loss of PIP2 bound GFP £uorescence from the
plasma membrane was observed. Fig. 1C demonstrates that,
5 min after stimulation of the same cell, PIP2 bound GFP
£uorescence was localized in the cytoplasm with no PIP2 spe-
ci¢c binding at the plasma membrane. This indicates that
ADP-stimulated PIP2 breakdown occurs in glioma C6 cells.
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To di¡erentiate whether ADP acts on one or two distinct
P2Y receptors in these cells, we performed knock-down of
P2Y1 receptor in C6 glioma cells with antisense oligonucleo-
tides [24]. To con¢rm the e¡ects of the protocol used, RT-
PCR was employed. Fig. 2 shows that, in the cells treated with
antisense oligonucleotides, the mRNA expression level of
P2Y1 receptor was very strongly reduced (lane 4). The
mRNA expression can be compared with control cells, un-
treated with antisense oligonucleotides (lane 3), or treated
with sense oligonucleotides (lane 5), where the P2Y1 mRNA
was fully expressed. As an additional control the glyceralde-
hyde 3-phosphate dehydrogenase expression level was tested
after transfection with antisense and sense oligonucleotides
and found to be unchanged under these conditions (not
shown).
In the next set of experiments, we examined the e¡ect of
knock-down of P2Y1 receptor on ADP-induced Ca2 mobi-
lization and the inhibition of the isoproterenol-elicited cAMP
accumulation (Fig. 3). The response to ADP in cells untreated
with antisense oligonucleotides was taken as 100% and re-
garded as the control (Fig. 3). This ADP response consisted
of both an increase in [Ca2]i level measured by digital £uo-
rescence microscopy and the inhibition of the level of cAMP.
As an additional control, we used the treatment of cells with
sense oligonucleotides, which showed the same response to
ADP as that observed in untreated cells. Fig. 3 shows that
PPADS, the antagonist of PLC-coupled P2Y1 receptor [14],
strongly inhibited the ADP-evoked [Ca2]i increase. A similar
e¡ect was observed with MRS2179, a structurally related nu-
cleotide. MRS2179, the speci¢c and selective antagonist of
Fig. 2. Antisense oligonucleotides induced a decrease in P2Y1 mRNA level. P2Y1 expression in control and treated cells was compared by RT-
PCR reaction. A 590 bp ampli¢cation product (corresponding to P2Y1 mRNA) was analyzed on 1% agarose gel and visualized by ethidium
bromide staining (for details see Section 2). Lane 1, molecular weight marker 123 bp; lane 2, control reaction in the absence of cDNA tem-
plate; lane 3, control cells; lane 4, cells treated with antisense oligonucleotide; lane 5, cells treated with control sense oligonucleotide. All the
reaction mixtures contained the same levels of template.
Fig. 1. ADP-stimulated PIP2 breakdown in glioma C6 cells. Digital micrographs are shown of the same cell before (A) and after (C) 5 min of
stimulation. The image shows the PIP2 bound GFP distribution. Arrows mark points in the images that are described in the text. B: Calcium
signal evoked by 10 WM ADP in the subjected cell. The data are representative of three independent experiments.
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P2Y1 receptor [25], completely blocked the ADP e¡ect on the
Ca2 increase. In contrast, PPADS and MRS2179 did not
abolish the ADP-induced cAMP inhibition. Knock-down of
C6 cells with P2Y1 antisense nucleotides markedly decreased
(about 50% of the control, consistent with the e⁄ciency of this
method, see Section 2.8) the ADP-induced intracellular Ca2
mobilization. In contrast, the ADP-evoked inhibition of ade-
nylyl cyclase was unchanged, indicating, together with the
e¡ects of antagonists of P2Y1 receptor, that two distinct
ADP-responding receptors coexist in glioma C6 cells.
To con¢rm the identity of the P2Y1-like receptor responsi-
ble for the inhibition of adenylyl cyclase in glioma C6 cells,
PCR on reverse-transcribed total mRNA was employed.
Primers were selected to cover the unique sequence of rat
platelets P2Y12 receptor. The estimated product size was 489
bp. Fig. 4 shows that mRNA of this receptor is expressed in
glioma C6 cells.
4. Discussion
It is now generally accepted that in non-excitable cells, such
as glioma C6 [18], biphasic capacitative Ca2 signaling is
mediated by the inositol system [26,27]. We have previously
characterized P2Y1 and P2Y2 receptors in glioma C6 cells
using measurements of [Ca2]i and demonstrated that ADP,
ATP and UTP initiated a large Ca2 response consistent with
the typical capacitative model of Ca2 entry, associated with
the stimulation of PLC and depletion of intracellular Ca2
stores [15]. In this process, the initial rise in [Ca2]i results
from the direct e¡ect of InsP3 on the endoplasmic reticulum
and can be observed even in the absence of extracellular Ca2
[28]. Our previous study showed that such Ca2 responses
were observed for all three nucleotides [15]. However, in con-
trast to ATP and UTP, the ADP-induced Ca2 response was
transient and quickly reduced to the basal level. Thus, one
could expect that ADP-evoked InsP3 accumulation was also
transient and too short to be estimated. Such a short Ca2
response was, most probably, the reason for the absence of a
detectable increase in InsP3 level in these cells and a former
belief that, in glioma C6, ADP-responding nucleotide receptor
stimulation does not lead to PLC activation [9,11,14]. Re-
cently, Grobben et al. [29] demonstrated the increase in the
InsP3 level after ADP stimulation for 30 min. However, this
increase was clearly seen at high concentrations of ADP, while
ADP at low concentration was still able to produce a transient
Ca2 response. The authors explained this observation by
PLC-independent Ca2 in£ux, evoked by P2Y1-like receptor
(P2YAC, recently classi¢ed as P2Y12).
The results of our previous study [15], and those presented
herein, strongly indicate that, in C6 glioma cells, ADP evokes
Ca2 response by activating the P2Y1 receptor, pharmacolog-
ically and molecularly identical to the cloned rat P2Y1 recep-
tor coupled to PLC. Therefore, we have concluded that in
these cells P2Y1 receptor stimulates PLC activation and is
e¡ective in the production of InsP3 and release of Ca2
from the endoplasmic reticulum stores. This conclusion was
proved by the direct visualization of PIP2 bound GFP £uo-
rescence. After the stimulation with ADP, the PIP2 bound
GFP £uorescence at the cell surface was distinctly reduced
with a simultaneous increase in [Ca2]i. These results show
the breakdown of PIP2 by activated PLC. It is worth adding
that no increase in the activity of phosphoinositide 3 kinase,
another enzyme utilizing PIP2 as a substrate, was observed
during the time of the experiment (not shown).
Knock-down of P2Y1 receptor with P2Y1 antisense oligo-
nucleotides markedly decreased the P2Y1 mRNA level and
evidently attenuated ADP-evoked intracellular Ca2 mobiliza-
Fig. 3. Comparison of the e¡ect of MRS2179, PPADS and anti-
sense oligonucleotide treatment on ADP-induced Ca2 mobilization
and the inhibition of isoproterenol-elicited cAMP response. For the
adenylyl cyclase assay, cells were treated with 50 WM isoproterenol
in the absence or presence of ADP (10 WM) for 5 min at 37‡C in
the standard bu¡er. cAMP levels were assayed with the [3H]cAMP
kit. The Ca2 assay was performed as described in Section 2. In the
experiments concerning adenylyl cyclase activity, the inhibition by
ADP of isoproterenol-evoked cAMP accumulation was taken as
100%. In the experiments concerning [Ca2]i the percentage of cells
responding to ADP in the standard manner [15] was taken as 100%.
MRS2179 (30 WM) and PPADS (100 WM) were added 2 min before
the experiments and together with the agonist. Antisense treatment
was performed as described in Section 2. The data are means þ S.D.
from four independent experiments performed in duplicate (cAMP
accumulation) or means þ S.D. from 10 independent experiments,
with about 50 cells analyzed in each experiment (Ca2 response).
Statistical signi¢cance of di¡erences is : ***P6 0.001, **P6 0.01
(Mann^Whitney test). AS, cells transfected with antisense oligonu-
cleotide; C, cells transfected with control sense oligonucleotides.
Fig. 4. Detection of P2Y12 mRNA by RT-PCR. A 489 bp ampli¢-
cation product (corresponding to P2Y12 mRNA) was analyzed on
1% agarose gel and visualized by ethidium bromide staining. Lane
1, molecular weight marker 123 bp; lane 2, control reaction in the
absence of cDNA template; lane 3, PCR product for P2Y12.
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tion, whereas the ADP e¡ect on adenylyl cyclase activity was
unchanged. Similarly, the speci¢c and selective P2Y1 receptor
antagonists, PPADS [14] and MRS2179 [25], completely
blocked the ADP-evoked increase in [Ca2]i and did not
change the cAMP level. These data elucidate the question
concerning the presence of one (coupled to di¡erent G pro-
teins) or two ADP-responding receptors in glioma C6 cells
and clearly indicate the latter case: one coupled to PLC and
elevated cytosolic Ca2 and the other responsible for adenylyl
cyclase down regulation.
To determine whether the ADP receptor coupled to adenyl-
yl cyclase in glioma C6 cells is the same as that recently cloned
from rat platelets and designated P2Y12 [16], we investigated
the expression of this receptor in C6 cells. RT-PCR analysis
revealed that P2Y12 is localized to these cells. The presence of
this receptor was also reported in glioma C6-2B cells [17]. In
platelets [16], C6-2B [17] and glioma C6 cells [15] this subtype
of receptor is sensitive to PTX, indicating that it is coupled to
adenylyl cyclase through Gi protein.
In conclusion, our data demonstrate that P2Y1 and P2Y12
receptor mRNAs are expressed in glioma C6 cells. ADP acts
on these two receptors: P2Y1, linked to the stimulation of
PLC and Ca2 release, and P2Y12, negatively coupled to ad-
enylyl cyclase through Gi protein.
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